Oncology experts drive the GIRO initiative to advocate for equitable access to radiotherapy as an essential part of multidisciplinary cancer care

Julie Torode

Current position
Based in Geneva, Julie Torode is Deputy CEO and Director of Advocacy and Networks for the Union for International Cancer Control (UICC). Julie joined UICC in 2008, where she has led the organisation’s advocacy activities, with a particular focus on equitable access to information, detection, diagnosis, treatment and care of cancer. Recent advocacy wins include a comprehensive update to the WHO model essential medicines list, a first-ever WHO guide of priority technologies for cancer and robust cost-effectiveness recommendations for cancer as part of the Global Action Plan on noncommunicable diseases 2013-2020 and the 2017 World Health Assembly cancer resolution.

A PhD Chemist  Julie has worked for almost 20 years in clinical trials, patient group management in oncology. Since joining UICC Julie has managed the flagship activities of TNM classification, International Journal of Cancer and developed UICC fellowships and other capacity building activities.

Main interests and Global collaborations / HE
Julie was a member of the International Secretariat of the Global Task Force in Radiotherapy on Cancer Control (GTFRCC) and contributed to the Lancet Oncology Commission. Julie leads UICCs  strategic partnerships with the World Health Organisation, International Agency for Research in Cancer and International Atomic Energy Agency and represents UICC in key international partnerships such as the Global Initiative on Cancer Registration and the International Cancer Control Partnership as well as new global alliances such NCD Alliance, Advanced Breast Cancer Alliance and McCabe Centre for Cancer and Law.

Short statement
Radiation therapy is recognised as an essential tool in the cure and palliation of cancer, needed by 50-60% of all cancer patients worldwide. GIRO is taking up the call to action of the GTFRCC lancet oncology commission urging all countries to invest inequitable access to this life-saving treatment.